

## AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED 31ST MARCH, 2015

Particulars	Standalone				Consolidated		
	Quarter ended		Year ended		Year ended		
	31/03/2015 Audited	31/12/2014 Unaudited	31/03/2014 Audited	31/03/2015 Audited	31/03/2014 Audited	31/03/2015 Audited	
Net Sales / Income from Operations	10531	6868	8124	31,845	29,417	31,849	29,505
Other Operating Income	249	131	209	714	779	724	779
<b>Total Income from operations</b>	<b>10780</b>	<b>6999</b>	<b>8333</b>	<b>32559</b>	<b>30196</b>	<b>32573</b>	<b>30285</b>
<b>Expenditure</b>							
Changes in Inventories of Finished Goods, Work-in-Progress and stocks-in-trade	870	223	(213)	337	(636)	337	(636)
Cost of Materials Consumed	6322	4,163	5350	20,713	18,750	20,720	18,832
Purchase of Stock-in-trade	25	16	217	131	578	131	578
Employee Benefits Expenses	867	751	546	2,883	2,296	2,883	2,301
Depreciation	(11)	330	320	958	1,246	964	1,292
Other Expenses	1711	1,140	1365	5,333	4,945	5,336	4,950
<b>Total Expenses</b>	<b>9784</b>	<b>6,623</b>	<b>7585</b>	<b>30,355</b>	<b>27,179</b>	<b>30,371</b>	<b>27,317</b>
<b>Profit (Loss) from operations before other income, interest and exceptional items</b>	<b>996</b>	376	748	<b>2,204</b>	3,017	2,202	2,968
Other Income	15	12	66	76	89	81	152
Foreign Exchange Gain/(Loss)	156	88	203	572	44	572	44
Profit (Loss) before interest and exceptional items	1,167	476	1,017	2,852	3,150	2,855	3,164
Finance Cost	376	324	402	1,297	1,446	1,297	1,446
<b>Profit (Loss) before exceptional items</b>	<b>791</b>	152	615	<b>1,555</b>	1,704	1,558	1,718
Exceptional items (Net)	(7)	-	-	(7)	-	(5,471)	-
<b>Profit (Loss) before tax</b>	<b>784</b>	152	615	<b>1,548</b>	1,704	(3,913)	1,718
Less: Tax expenses	-	-	-	-	-	-	-
<b>Net Profit (Loss) for the year</b>	<b>784</b>	152	615	<b>1,548</b>	1,704	(3,913)	1,718
Paid up equity share Capital (Face value Rs 10/-)	4,110	4,110	3,905	4,110	3,905	4,110	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	12,181	9,752	3,465	6,693
Earning Per Share (EPS) Before Exceptional Item							
a) Basic	1.99	0.38	1.58	3.91	4.36	3.92	4.40
b) Diluted	1.99	0.38	1.58	3.91	4.36	3.92	4.40
Earning Per Share (EPS) after Exceptional Item							
a) Basic	1.97	0.38	1.58	3.89	4.36	(9.84)	4.40
b) Diluted	1.97	0.38	1.58	3.89	4.36	(9.84)	4.40
<b>Part II</b>							
<b>(A) PARTICULARS OF SHAREHOLDING</b>							
Public shareholding							
Number of shares	23805963	23753463	23753463	23805963	23753463	23705963	23753463
Percentage of shareholding	57.92%	57.80%	60.83%	57.92%	60.83%	57.92%	60.83%
<b>Promoters and Promoter Group Shareholding</b>							
<b>a) Pledged / Encumbered</b>							
Number of shares	3300000	3352500	3352500	3300000	3352500	3300000	3352500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.08%	19.33%	21.92%	19.08%	21.92%	19.08%	21.92%
Percentage of shares (as a % of the total share capital of the company)	8.03%	8.16%	8.59%	8.03%	8.59%	8.03%	8.59%
<b>b) Non - encumbered</b>							
Number of shares	13993513	13993513	11943513	13993513	11943513	13993513	11943513
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	80.92%	80.67%	78.08%	80.92%	78.08%	80.92%	78.08%
Percentage of shares (as a % of the total share capital of the company)	34.05%	34.05%	30.58%	34.05%	30.58%	34.05%	30.58%
<b>(B) INVESTOR COMPLAINTS</b>							
				<b>3 Months ended 31-03-2015</b>			
Pending at the beginning of the quarter							-
Received during the quarter							3
Disposed off during the quarter							3
Unresolved at the end of the quarter							-
<b>Reporting of Segment wise Revenue, Result and Capital Employed</b>							
Particulars	Standalone						
	Quarter ended		Year ended				
	31/03/2015 Audited	31/12/2014 Unaudited	31/03/2014 Audited	31/03/2015 Audited	31/03/2014 Audited		
<b>1. Segment Revenue</b>							
(a) Pharmaceutical	11,020	7,144	8,542	33,209	30,880		
(b) Consumer Care Division	68	60	61	254	246		
<b>Total</b>	<b>11,088</b>	<b>7,204</b>	<b>8,603</b>	<b>33,463</b>	<b>31,126</b>		
Less: Inter-Segment Revenue	-	-	-	-	-		
Less: Excise Duty	308	205	270	904	930		
<b>Net Sales/ Income from Operation</b>	<b>10,780</b>	<b>6,999</b>	<b>8,333</b>	<b>32,559</b>	<b>30,196</b>		
<b>2. Segment Results</b>							
(a) Pharmaceutical	1,261	526	1,108	3,133	3,417		
(b) Consumer Care Division	(94)	(50)	(91)	(281)	(267)		
<b>Total</b>	<b>1,167</b>	<b>476</b>	<b>1,017</b>	<b>2,852</b>	<b>3,150</b>		
Less: Finance Cost	376	324	402	1,297	1,446		
<b>Total Profit Before Tax</b>	<b>791</b>	<b>152</b>	<b>615</b>	<b>1,555</b>	<b>1,704</b>		
<b>3. Capital Employed</b>							
(a) Pharmaceutical	5,915	21,490	21,556	5,915	21,556		
(b) Consumer Care Division	746	652	397	746	397		
(c) Others (Unallocated)	15,688	5,407	5,416	15,688	5,416		
<b>Total</b>	<b>22,349</b>	<b>27,549</b>	<b>27,370</b>	<b>22,349</b>	<b>27,370</b>		

### Notes:-

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 28th May, 2015. These results have been audited by the Statutory Auditor's of the company.
- The figures for the quarter ended 31st March, 2015 are the balancing figures between audited figures in respect of full financial year ended 31st March, 2015 and the unaudited published year to date figures upto the 3rd quarter ended 31st December, 2014.
- The Company has revised its accounting policy in respect of depreciation method on tangible assets, other than factory building and plant and machinery, from 'written own value method' to 'straight line method' over the expected useful life of the assets. The management is of the opinion that this change in accounting policy would result in a more appropriate presentation of the financial statements. As a result of this change, depreciation has been calculated retrospectively on straight line method and accordingly the Company has recorded reversal of depreciation expense amounting to Rs. 263.04 lacs pertaining to previous years in the current year's Statement of Profit & Loss.

The Company has also revised the estimate useful life of assets, except plant and machinery, as prescribed in schedule II of the Companies Act, 2013. The carrying value of assets where the remaining useful life was determined to be nil as on April 1, 2014 has been fully depreciated during the year and an amount of Rs. 266.95/- Lacs has been adjusted against the opening balance of profit and loss account in the balance sheet under Reserves and Surplus

Consequent to the above changes, the depreciation expense in the Statement of Profit and Loss for the year is lower by Rs. 85.88/- Lacs (excluding impact of depreciation written back in respect of previous years).

- Exceptionation items consist of -
  - in standalone financial statements - gain on slump sale of API business Rs. 728/- lac and advances written off Rs. 735/- lacs
  - in consolidated financial statements - capital work in progress written off Rs. 1,892/- lacs and loss on intragroup slump sale charged to revenue Rs. 3,578/- lacs

Particulars	Continuing operations		Discontinuing operations	
	For the year 2014-15	For the year 2013-14	For the year 2014-15	For the year 2013-14
Profit/(loss) from ordinary activities	19,146	17,626	14,068	12,704
Income	18,036	16,368	13,623	12,257
Less: Expenses	1,110	1,258	445	446
Profit before tax	-	-	-	-
Less: Tax expense	1,110	1,258	445	446
Profit after tax	1,110	1,258	445	446

- The following statement shows the bifurcation of income and expenses of continuing and discontinuing operations included under the statement of profit and loss:

Particulars	As on 31-03-2015	
	Continuing operations	Discontinuing operations
Total assets	18,077	7,805
Total liabilities	10,272	11,000
Net assets transferred	7,805	728
Consideration	11,000	-
Gain on slump sale	728	-

- The carrying amount of total assets and liabilities of discontinuing operations are as follows:

(6) The Company, during the year, has issued preferential shares and warrants of Rs. 27.72 Crores to promoter group company against adjustment of outstanding loan.

(7) Figures for the previous accounting period have been regrouped wherever necessary.

### (8) Statement of Assets and Liabilities as at 31st March, 2015

Particulars	Standalone		Consolidated	
	As at year ended 31-03-2015	As at year ended 31-03-2014	As at year ended 31-03-2015	As at year ended 31-03-2014
	Audited	Audited	Audited	Audited
<b>I. EQUITY AND LIABILITIES</b>				
<b>1. Shareholders Funds</b>				
(a) Share Capital	4968	4763	4968	4763
(b) Reserves and Surplus	12181	9752	3465	6693
(c) Money received against share warrants	1419	-	1419	-
<b>Total</b>	<b>18568</b>	<b>14515</b>	<b>9852</b>	<b>11456</b>
<b>2. Non-current liabilities</b>				
(a) Long-term borrowings	753	6322	1401	6323
(b) Other Long-term liabilities	-	-	-	25
(c) Long-term provisions	273	355	430	354
<b>Total</b>	<b>1026</b>	<b>6677</b>	<b>1831</b>	<b>6702</b>
<b>3. Current liabilities</b>				
(a) Short-term borrowings	1841	5226	5138	5227
(b) Trade payables	3634	3549	6922	3571
(c) Other current liabilities	2305	2918	3670	2933
(d) Short-term provisions	88	14	90	14
<b>Total</b>	<b>7868</b>	<b>11707</b>	<b>15820</b>	<b>11745</b>
<b>TOTAL</b>	<b>27462</b>	<b>32899</b>	<b>27503</b>	<b>29903</b>
<b>II. ASSETS</b>				
<b>1. Non-current assets</b>				
(a) Fixed Assets				
(i) Tangible assets	3346	10266	10155	10488
(ii) Intangible assets	0	-	1	1
(iii) Capital work-in-progress	19	84	123	1977
(b) Non-current investment	4607	687	11	81
(c) Long-term loans and advances	175	5831	215	1386
<b>Total</b>	<b>8147</b>	<b>16868</b>	<b>10505</b>	<b>13933</b>
<b>2. Current assets</b>				
(a) Inventories	1406	5302	4530	5302
(b) Trade receivables	2906	5464	8117	5603
(c) Cash and Bank balances	362	454	373	472
(d) Short-term loans and advances	14641	4811	3978	4593
<b>Total</b>	<b>19315</b>	<b>16031</b>	<b>16998</b>	<b>15970</b>
<b>TOTAL</b>	<b>27462</b>	<b>32899</b>	<b>27503</b>	<b>29903</b>